Global Transcatheter (percutaneous) Mitral Valve Market: By Product Type (Transfemoral implantation, Transapical implantation), By Distribution Channel (Hospitals, Cardiac care centers, Others), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024
Global transcatheter (percutaneous) mitral valve market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over the 2018 to 2024.
Market Outline: Transcatheter (percutaneous) Mitral Valve Market
Transcatheter (percutaneous) mitral valve is used to treat mitral regurgitation (MR). Mitral valve disease is the second most common valvular heart disease in adults. MR is classified as either primary (degenerative) or secondary (functional). Primary MR from degenerative valve disease is due to a primary disruption of the mitral valve apparatus from either prolapsed or flail leaflets. Secondary MR on the other hand is due to remodeling of the left ventricle resulting inappropriate coaptation of the mitral leaflets. Trans catheter heart valve implantation procedure helps in replacing the heart valve with prosthetic valve for treatment of severe aortic stenosis and mitral regurgitation. This increases survival rate of patients and helps in reducing severe degenerative aortic stenosis.
Market Dynamics: Transcatheter (percutaneous) Mitral Valve Market
Increase in the prevalence of cardiac disorders and increasing aging population are expected to drive the market. The increasing demand for less invasive procedure for high risk patients, severe aortic stenosis disorder and growing prevalence of mitral regurgitation are expected to drive the growth of Transcatheter (percutaneous) mitral valve market. Furthermore, conditions like speedy recovery, shorter span of time required for the patient to stay in the hospital are favoring the implantation of the transcatheter (percutaneous) mitral valve implantation. However, the high costs of the transcatheter heart valves, risk involved in the procedure such as improper positioning of the implant and device related issues such as product recalls by the manufacturers are expected to hamper the growth of transcatheter (percutaneous) mitral valve market.
Free sample of this report is available upon request @
Market Scope: Transcatheter (percutaneous) Mitral Valve Market
Transcatheter (percutaneous) mitral valve market is segmented based on the product type, and distribution channel
Based on the product type, the market is segmented into the following:
- Transfemoral implantation
- Transapical implantation
Based on the distribution channel, the market is segmented into the following:
- Hospitals
- Cardiac care centers
- Others
Free TOC of this report is available upon request @
Regional Analysis: Transcatheter (percutaneous) Mitral Valve Market
Geographically, global transcatheter (percutaneous) mitral valve market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America transcatheter (percutaneous) mitral valve market is growing at unprecedented rate due to increase in the prevalence of cardiac disorders and increasing incidences of mitral valve disorders. The increasing geriatric population, high number of cases of congenital heart defects which is driving the growth of the transcatheter (percutaneous) mitral valve market in this region. The improving technological advancements and rising government funds are expected to drive the market in Europe. Furthermore, in emerging countries of Asia, increasing focus on investigational product and awareness about the treatment procedures among the patient pool is driving the transcatheter (percutaneous) mitral valve market in this region.
Need more information about this report @
Competition Assessment: Transcatheter (percutaneous) Mitral Valve Market
Some of the players in the global transcatheter (percutaneous) mitral valve market include:
- Boston Scientific Corporation (U.S)
- Abbott Laboratories (U.S)
- Edwards Lifesciences Corporation
- Micro Interventional Devices (U.S)
- Neochord Inc. (U.S)
- Medtronic, Inc. (U.S)
- Jude Medical, Inc. (U.S)
- JenaValve Technology (U.S)
- Livanova Plc, (U.K)
- Colibri Heart Valve, Llc. (U.S)
- Neovasc (Canada)
- Biotronik SE & Co. KG (Germany)
Notable Market Developments: Transcatheter (percutaneous) Mitral Valve Market
- In Feburary 2018, Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, has announced that it has received CE Mark for its self-expanding CENTERA valve for severe, symptomatic aortic stenosis patients at high risk of open-heart surgery.
Get access to full summary @
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com